Pohjois-Pohjanmaan hyvinvointialue
- Address
- lock Available on a paid plan
Pohjois-Pohjanmaan hyvinvointialue - Comprehensive Clinical Research Center
Pohjois-Pohjanmaan hyvinvointialue is a multidisciplinary research center with extensive expertise in pediatric oncology and hematological malignancies. The center demonstrates particular strength in childhood cancer research, participating in international cooperative group trials for complex pediatric tumors and leukemias. Their research portfolio spans from early-phase dose-finding studies to large-scale randomized controlled trials, reflecting a commitment to advancing treatment protocols across multiple age groups.
- Pediatric brain tumors including ependymoma, medulloblastoma, and high-risk medulloblastoma with advanced molecular profiling
- Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in children, adolescents, and young adults, including Philadelphia chromosome-positive ALL and relapsed disease
- Solid tumors including rhabdomyosarcoma and advanced prostate cancer with novel therapeutic combinations
- Neonatal respiratory medicine, pulmonary fibrosis, metabolic disorders, and weight management interventions
The center actively contributes to international study groups including SIOP, NOPHO, and BFM consortia, enabling access to cutting-edge targeted therapies and immunotherapies. Their research encompasses precision medicine approaches with molecular risk stratification, minimal residual disease monitoring, and advanced imaging techniques. Beyond oncology, the center conducts important studies in neonatal care, cardiovascular risk factors, and metabolic interventions, demonstrating a comprehensive approach to improving patient outcomes across the lifespan.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 77 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 75 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Genmab A/S2active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Genmab A/S2trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pohjois-Pohjanmaan hyvinvointialue
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 77 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Vincristine Sulfate | 5 | Unknown | 2017-10-02 | 2021-11-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.